Table 2.
Risk of Disability Pension, Risk Difference Between Subgroups (Crude and Adjusted for Sex and Age) for Patients with Lymphoma 5 Years After Index Date with 95% Confidence Interval
| Risk (%) | RD (Crude) | RD (Adjusted) | |
|---|---|---|---|
| Sex | |||
| Male | 7.0 (5.9;8.0) | 0 | |
| Female | 9.5 (8.1;11.0) | 2.5 (0.8;4.3) | |
| Age at diagnosis | |||
| 18–30 years | 2.7 (1.5;3.9) | 0 | |
| 31–40 years | 5.3 (3.6;7.0) | 2.5 (0.5;4.6) | |
| 41–50 years | 7.7 (6.0;9.4) | 5.0 (2.9;7.1) | |
| 51–60 years | 11.9 (10.3;13.6) | 9.2 (7.2;11.2) | |
| Year of diagnosis | |||
| 2000–2004 | 9.9 (8.1;11.8) | 0 | 0 |
| 2005–2009 | 9.7 (7.9;11.5) | −0.2 (−2.9;2.5) | −0.3 (−2.9;2.4) |
| 2010–2014 | 5.5 (4.1;6.9) | −4.5 (−6.9;-2.1) | −4.2 (−6.6;-1.8) |
| 2015–2019 | 7.3 (5.4;9.2) | −2.7 (−5.2;-0.3) | −2.5 (−5.0;-0.1) |
| Cohabiting status | |||
| Living alone | 10.6 (8.7;12.4) | 0 | 0 |
| Living with partner | 7.0 (6.1;8.0) | −3.5 (−5.6;-1.5) | −4.9 (−6.9;-2.8) |
| Education level | |||
| ISCED 0–2 | 12.9 (10.8;15.1) | 0 | 0 |
| ISCED 3 | 7.3 (6.1;8.5) | −5.7 (−8.2;-3.2) | −5.4 (−7.9;-2.9) |
| ISCED 5–6 | 5.1 (3.6;6.6) | −7.8 (−10.5;-5.2) | −8.2 (−10.8;-5.6) |
| ISCED 7–8 | 3.3 (1.4;5.2) | −9.7 (−12.6;-6.8) | −9.5 (−12.4;-6.6) |
| Equalized income | |||
| Lowest | 15.6 (13.1;18.1) | 0 | 0 |
| Second lowest | 9.0 (7.2;10.8) | −6.5 (−9.5;-3.4) | −7.3 (−10.3;-4.3) |
| Second highest | 6.0 (4.5;7.5) | −9.5 (−12.4;-6.6) | −10.2 (−13.1;-7.4) |
| Highest | 3.2 (2.2;4.3) | −12.3 (−15.0;-9.6) | −12.8 (−15.5;-10.1) |
| Consecutive sick leave min. 4 weeks within the year before diagnosis | |||
| No sick leave | 5.8 (5.0;6.6) | 0 | 0 |
| Sick leave | 18.3 (15.4;21.1) | 12.4 (9.5;15.4) | 11.5 (8.6;14.5) |
| Charlson Comorbidity Index | |||
| 0-1 | 7.4 (6.5;8.2) | 0 | 0 |
| 2 | 15.3 (10.3;20.3) | 8.0 (2.9;13.0) | 6.0 (1.0;11.0) |
| ≥ 3 | 16.7 (9.8;23.6) | 9.1 (2.3;16.0) | 8.1 (1.1;15.1) |
| Lymphoma type | |||
| Hodgkin Lymphoma | 4.7 (3.5;5.9) | 0 | 0 |
| Non-Hodgkin Lymphoma | 9.6 (8.5;10.7) | 4.9 (3.3;6.5) | 1.9 (0.0;3.8) |
| Lymphoma subtype | |||
| DLBCL | 10.4 (8.7;12.1) | 0 | 0 |
| Nodular lymphocyte predominant | 3.9 (0.0;8.3) | −6.4 (−11.1;-1.7) | −3.3 (−8.0;1.4) |
| Classical Hodgkin lymphoma | 4.7 (3.5;6.0) | −5.7 (−7.7;-3.6) | −2.5 (−4.9;-0.2) |
| Indolent lymphomas | 8.1 (6.3;10.0) | −2.3 (−4.8;0.2) | −3.0 (−5.6;-0.5) |
| Intermediate lymphomas | 8.7 (4.0;13.5) | −1.7 (−6.7;3.3) | −2.8 (−7.9;2.4) |
| Aggressive T-cell lymphomas | 13.3 (8.8;17.8) | 2.9 (−2.0;7.7) | 3.9 (−0.9;8.7) |
| Other aggressive B-cell lymphomas | 5.1 (1.4;8.7) | −5.4 (−9.4;-1.3) | −2.0 (−6.1;2.2) |
| Other | 10.9 (4.1;17.6) | 0.3 (−6.5;7.2) | 0.6 (−6.2;7.5) |
| Ann Arbor | |||
| 1–2 | 6.2 (5.2;7.3) | 0 | 0 |
| 3–4 | 10.0 (8.6;11.4) | 3.8 (2.0;5.5) | 2.9 (1.2;4.7) |
| ECOG Performance Status | |||
| 0-1 | 7.4 (6.5;8.2) | 0 | 0 |
| 2–4 | 20.1 (14.6;25.6) | 12.8 (7.1;18.5) | 12.3 (6.7;17.9) |
Abbreviations: RD, risk difference; ISCED, International Standard Classification of Education; DLBCL, diffuse large B cell lymphoma.